跳至主要内容
临床试验/IRCT20150101020514N8
IRCT20150101020514N8招募中2 期

Comparative evaluation of the safety and efficacy of botulinum toxin type A (product of Imen Vaccine Alborz CO) in comparison with Dysport (standard treatment) for treating glabellar rhytids in people with moderate to severe glabellar rhytids.

Imen vaccine alborz Company0 个研究点目标入组 140 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
140

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 75 years(—)
性别
All

入选标准

  • Men and women with 18 to 75 years old
  • mild to moderate Glabellar Lines
  • signing informed consent form

排除标准

  • Hypersensitivity to botulinum toxin or other components of formulation
  • History of treatment with botulinum toxin in face area within the past 6 months
  • History of using aminoglycosides, penicillin, kinin, chloroquine,Calcium Channel Blockers, warfarin and aspirin
  • History of injectable filler, chemical peels and laser treatment of any type within the past year
  • Significant scarring ,skin disorder or wound infection in the facial area
  • Neuro-muscular disorders like miastenia gravis, iron lambert , ALS
  • Significant face asymmetry
  • Any active, chronic and recurrent infection
  • Pregnancy/ breast feeding

研究者

发起方
Imen vaccine alborz Company

相似试验